<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02936999</url>
  </required_header>
  <id_info>
    <org_study_id>16-2399</org_study_id>
    <nct_id>NCT02936999</nct_id>
  </id_info>
  <brief_title>Vitamin D Supplementation in Women With DCIS and/or LCIS</brief_title>
  <official_title>An Exploratory Pilot Study of Vitamin D Supplementation in Women With DCIS and/or LCIS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inova Health Care Services</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inova Health Care Services</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and usefulness of oral Vitamin D&#xD;
      supplementation in subjects with in situ carcinoma. More specifically, this study is being&#xD;
      done to (1) understand the effect of Vitamin D supplementation on behavior of breast cancer&#xD;
      cells and (2) the development of invasive breast cancer disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In vitro, calcitriol, the most potent metabolite of vitamin D, inhibits a variety of cellular&#xD;
      pathways that promote cell proliferation and survival. Vitamin D has been shown to reduce the&#xD;
      growth of breast cancer precursor cells in cell culture studies. In animal models Vitamin D&#xD;
      has been shown to prevent the growth and progression of transplanted cell lines MCF710A,&#xD;
      which is a model of pre-invasive cancer. Serum Vitamin D level deficiency correlates with an&#xD;
      increased risk of breast cancer, and reduced survival of breast cancer patients. Vitamin D is&#xD;
      also recognized to have effects on immune cell function and autoimmunity. The safety profile&#xD;
      of oral Vitamin D, and its metabolite calcitriol, was well established for moderate term and&#xD;
      acute therapy worldwide. Potential additional primary and secondary benefits of vitamin D are&#xD;
      a) the suppression of carcinogen-induced transformation or progression of breast epithelium,&#xD;
      and b) the enhancement of innate immune defense of pre-invasive breast cancer lesions, and c)&#xD;
      its qualification as a combination therapy when combined with other neoadjuvant therapies for&#xD;
      DCIS.&#xD;
&#xD;
      Patients who have been diagnosed by core biopsy with carcinoma in situ, ductal or lobular,&#xD;
      will be evaluated for vitamin d supplementation. Patients with vitamin d levels less than 50&#xD;
      will be eligible for participation. They will receive a one month (30 days) schedule of&#xD;
      vitamin D supplementation and then proceed with the standard of care of surgical excision.&#xD;
      Immunohistochemistry studies will be performed on the diagnostic core biopsy and the surgical&#xD;
      specimen to evaluate the impact of vitamin d supplementation on: the proliferative&#xD;
      index-ki67, proliferative marker- PCNA, proteins of the autophagy pathway (LC3B, ATG7), her2&#xD;
      localization, and levels of PMCA2 - calcium efflux channel.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated for lack of patient samples and funding&#xD;
  </why_stopped>
  <start_date type="Actual">August 2016</start_date>
  <completion_date type="Actual">January 2019</completion_date>
  <primary_completion_date type="Actual">January 2019</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ki 67 Measured</measure>
    <time_frame>28 days +/- 3 days from Day 1 of treatment</time_frame>
    <description>The proliferation index measured by Ki67 will be described for both baseline (pre) and surgical (post) vitamin D supplementation. A paired t-test or the non-parametric Wilcoxon signed-rank test will be used when appropriate to compare patients' outcome between baseline and after-treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Levels of Proteins of the Autophagy Pathway, LC3B</measure>
    <time_frame>28 days +/- 3 days from Day 1 of treatment</time_frame>
    <description>Descriptive statistics (N, mean, median, Min, Max, STD for continuous variables, and N, proportion for categorical variables) will be used to summarize patients' demographics as well as lab results. . A paired t-test or the non-parametric Wilcoxon signed-rank test will be used when appropriate to compare patients' outcome between baseline and after-treatment. A p-value of &lt;0.05 will be considered statistically significant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of Proteins of the Autophagy Pathway, ATG7</measure>
    <time_frame>28 days +/- 3 days from Day 1 of treatment</time_frame>
    <description>Descriptive statistics (N, mean, median, Min, Max, STD for continuous variables, and N, proportion for categorical variables) will be used to summarize patients' demographics as well as lab results. . A paired t-test or the non-parametric Wilcoxon signed-rank test will be used when appropriate to compare patients' outcome between baseline and after-treatment. A p-value of &lt;0.05 will be considered statistically significant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of the Calcium Transport Proteins, PMCA2</measure>
    <time_frame>28 days +/- 3 days from Day 1 of treatment</time_frame>
    <description>Descriptive statistics (N, mean, median, Min, Max, STD for continuous variables, and N, proportion for categorical variables) will be used to summarize patients' demographics as well as lab results. A paired t-test or the non-parametric Wilcoxon signed-rank test will be used when appropriate to compare patients' outcome between baseline and after-treatment. A p-value of &lt;0.05 will be considered statistically significant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HER2 Localization</measure>
    <time_frame>28 days +/- 3 days from Day 1 of treatment</time_frame>
    <description>Descriptive statistics (N, mean, median, Min, Max, STD for continuous variables, and N, proportion for categorical variables) will be used to summarize patients' demographics as well as lab results. A paired t-test or the non-parametric Wilcoxon signed-rank test will be used when appropriate to compare patients' outcome between baseline and after-treatment. A p-value of &lt;0.05 will be considered statistically significant.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Vitamin D3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be dispensed cholecalciferol, 32 capsules/bottle of 1cap/4000 IU PO QD on Day 1 visit to take home. Bottle must be labeled with instructions on how to take the drug and the assigned patient ID number. Patients will be instructed to take 1 capsule per day, with water, for 29 days using the dispensed study bottle. They will be instructed to stop taking their daily vitamin D3 dose after 30 days of treatment. A study drug diary will be provided at Day 1 visit and patients will be instructed to complete the study drug diary daily from Day 2 to Day 30. Patient's report of vitamin-D3 intake from the diary must be reconciled against the number of capsules returned at Day 30 visit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecalciferol</intervention_name>
    <description>Cholecalciferol 100,000 IU followed by 4000 IU orally once daily for 30 days.</description>
    <arm_group_label>Vitamin D3</arm_group_label>
    <other_name>Vitamin D3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must have a tissue diagnosis of lobular carcinoma in situ or ductal carcinoma&#xD;
             in situ and being scheduled to undergo excision of their cancer&#xD;
&#xD;
          -  Subjects must be female at least 18 years of age&#xD;
&#xD;
          -  Subjects must have a signed consent&#xD;
&#xD;
          -  Normal liver function based on (total bilirubin and AST &lt;1.5 x Upper Limit of Normal)&#xD;
&#xD;
          -  Serum creatinine &lt; 2.0 mg/dL&#xD;
&#xD;
          -  Serum 25 (OH) D levels &lt; 50 ng/ml&#xD;
&#xD;
          -  Calcium within the normal range (8.5-10.2 mg/dL)&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Are able to swallow and retain oral medication&#xD;
&#xD;
          -  Subjects should be willing to abstain from use of hormonal therapies (e.g. hormone&#xD;
             replacement therapy, oral contraceptive pills, hormone-containing IUDs, and E-string)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient desires not to participate in the study&#xD;
&#xD;
          -  Inability to give consent&#xD;
&#xD;
          -  Current use of hormone-containing forms of birth control such as implants (i.e.&#xD;
             Norplants, or injectables (i.e. depo-provera)&#xD;
&#xD;
          -  Currently lactating&#xD;
&#xD;
          -  Patients with history of renal or hepatic insufficiency&#xD;
&#xD;
          -  Used an investigational drug within 30 days or 5 half-lives, whichever is longer,&#xD;
             preceding the first dose of study medication&#xD;
&#xD;
          -  History of granulomatous disease such as tuberculosis or sarcoidosis&#xD;
&#xD;
          -  History of Vitamin D supplementation &gt; 2000 IU/day within the last 2 months&#xD;
&#xD;
          -  History of hypoparathyroidism&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary Wilkinson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inova Schar Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Inova Schar Cancer Institute</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bernardes JR Jr, Nonogaki S, Seixas MT, Rodrigues de Lima G, Baracat EC, Gebrim LH. Effect of a half dose of tamoxifen on proliferative activity in normal breast tissue. Int J Gynaecol Obstet. 1999 Oct;67(1):33-8.</citation>
    <PMID>10576237</PMID>
  </reference>
  <reference>
    <citation>Chen YY, DeVries S, Anderson J, Lessing J, Swain R, Chin K, Shim V, Esserman LJ, Waldman FM, Hwang ES. Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ. BMC Cancer. 2009 Aug 18;9:285. doi: 10.1186/1471-2407-9-285.</citation>
    <PMID>19689789</PMID>
  </reference>
  <reference>
    <citation>Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer. 2007 Sep;7(9):684-700. Review.</citation>
    <PMID>17721433</PMID>
  </reference>
  <reference>
    <citation>Espina V, Edmiston KH, Liotta LA. Non-enzymatic, serum-free tissue culture of pre-invasive breast lesions for spontaneous generation of mammospheres. J Vis Exp. 2014 Nov 8;(93):e51926. doi: 10.3791/51926.</citation>
    <PMID>25406584</PMID>
  </reference>
  <reference>
    <citation>Espina V, Liotta LA. What is the malignant nature of human ductal carcinoma in situ? Nat Rev Cancer. 2011 Jan;11(1):68-75. doi: 10.1038/nrc2950. Epub 2010 Dec 2. Review.</citation>
    <PMID>21150936</PMID>
  </reference>
  <reference>
    <citation>Espina V, Mariani BD, Gallagher RI, Tran K, Banks S, Wiedemann J, Huryk H, Mueller C, Adamo L, Deng J, Petricoin EF, Pastore L, Zaman S, Menezes G, Mize J, Johal J, Edmiston K, Liotta LA. Malignant precursor cells pre-exist in human breast DCIS and require autophagy for survival. PLoS One. 2010 Apr 20;5(4):e10240. doi: 10.1371/journal.pone.0010240.</citation>
    <PMID>20421921</PMID>
  </reference>
  <reference>
    <citation>Esserman L. Neoadjuvant chemotherapy for primary breast cancer: lessons learned and opportunities to optimize therapy. Ann Surg Oncol. 2004 Jan;11(1 Suppl):3S-8S. Review.</citation>
    <PMID>15015703</PMID>
  </reference>
  <reference>
    <citation>Esserman L, Sepucha K, Ozanne E, Hwang ES. Applying the neoadjuvant paradigm to ductal carcinoma in situ. Ann Surg Oncol. 2004 Jan;11(1 Suppl):28S-36S.</citation>
    <PMID>15015707</PMID>
  </reference>
  <reference>
    <citation>Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998 Sep 16;90(18):1371-88.</citation>
    <PMID>9747868</PMID>
  </reference>
  <reference>
    <citation>Gandini S, Boniol M, Haukka J, Byrnes G, Cox B, Sneyd MJ, Mullie P, Autier P. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int J Cancer. 2011 Mar 15;128(6):1414-24. doi: 10.1002/ijc.25439.</citation>
    <PMID>20473927</PMID>
  </reference>
  <reference>
    <citation>Gonzalez RJ, Buzdar AU, Fraser Symmans W, Yen TW, Broglio KR, Lucci A, Esteva FJ, Yin G, Kuerer HM. Novel clinical trial designs for treatment of ductal carcinoma in situ of the breast with trastuzumab (herceptin). Breast J. 2007 Jan-Feb;13(1):72-5.</citation>
    <PMID>17214797</PMID>
  </reference>
  <reference>
    <citation>Hathcock JN, Shao A, Vieth R, Heaney R. Risk assessment for vitamin D. Am J Clin Nutr. 2007 Jan;85(1):6-18. Review.</citation>
    <PMID>17209171</PMID>
  </reference>
  <reference>
    <citation>Alipour S, Hadji M, Hosseini L, Omranipour R, Saberi A, Seifollahi A, Bayani L, Shirzad N. Levels of serum 25-hydroxy-vitamin d in benign and malignant breast masses. Asian Pac J Cancer Prev. 2014;15(1):129-32.</citation>
    <PMID>24528013</PMID>
  </reference>
  <reference>
    <citation>Hird RB, Chang A, Cimmino V, Diehl K, Sabel M, Kleer C, Helvie M, Schott A, Young J, Hayes D, Newman L. Impact of estrogen receptor expression and other clinicopathologic features on tamoxifen use in ductal carcinoma in situ. Cancer. 2006 May 15;106(10):2113-8.</citation>
    <PMID>16596655</PMID>
  </reference>
  <reference>
    <citation>Hwang ES, Esserman L. Neoadjuvant hormonal therapy for ductal carcinoma in situ: trial design and preliminary results. Ann Surg Oncol. 2004 Jan;11(1 Suppl):37S-43S.</citation>
    <PMID>15015708</PMID>
  </reference>
  <reference>
    <citation>Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49. doi: 10.3322/caac.20006. Epub 2009 May 27.</citation>
    <PMID>19474385</PMID>
  </reference>
  <reference>
    <citation>Jeong Y, Swami S, Krishnan AV, Williams JD, Martin S, Horst RL, Albertelli MA, Feldman BJ, Feldman D, Diehn M. Inhibition of Mouse Breast Tumor-Initiating Cells by Calcitriol and Dietary Vitamin D. Mol Cancer Ther. 2015 Aug;14(8):1951-61. doi: 10.1158/1535-7163.MCT-15-0066. Epub 2015 May 1.</citation>
    <PMID>25934710</PMID>
  </reference>
  <reference>
    <citation>Kaur P, Mishra SK, Mithal A. Vitamin D toxicity resulting from overzealous correction of vitamin D deficiency. Clin Endocrinol (Oxf). 2015 Sep;83(3):327-31. doi: 10.1111/cen.12836. Epub 2015 Jul 14.</citation>
    <PMID>26053339</PMID>
  </reference>
  <reference>
    <citation>Kumar AS, Bhatia V, Henderson IC. Overdiagnosis and overtreatment of breast cancer: rates of ductal carcinoma in situ: a US perspective. Breast Cancer Res. 2005;7(6):271-5. Epub 2005 Nov 11.</citation>
    <PMID>16457703</PMID>
  </reference>
  <reference>
    <citation>Giammanco M, Di Majo D, La Guardia M, Aiello S, Crescimannno M, Flandina C, Tumminello FM, Leto G. Vitamin D in cancer chemoprevention. Pharm Biol. 2015;53(10):1399-434. doi: 10.3109/13880209.2014.988274. Epub 2015 Apr 9. Review.</citation>
    <PMID>25856702</PMID>
  </reference>
  <reference>
    <citation>Lee O, Page K, Ivancic D, Helenowski I, Parini V, Sullivan ME, Margenthaler JA, Chatterton RT Jr, Jovanovic B, Dunn BK, Heckman-Stoddard BM, Foster K, Muzzio M, Shklovskaya J, Skripkauskas S, Kulesza P, Green D, Hansen NM, Bethke KP, Jeruss JS, Bergan R, Khan SA. A randomized phase II presurgical trial of transdermal 4-hydroxytamoxifen gel versus oral tamoxifen in women with ductal carcinoma in situ of the breast. Clin Cancer Res. 2014 Jul 15;20(14):3672-82. doi: 10.1158/1078-0432.CCR-13-3045.</citation>
    <PMID>25028506</PMID>
  </reference>
  <reference>
    <citation>Leonard GD, Swain SM. Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst. 2004 Jun 16;96(12):906-20. Review.</citation>
    <PMID>15199110</PMID>
  </reference>
  <reference>
    <citation>Li CI, Malone KE, Saltzman BS, Daling JR. Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988-2001. Cancer. 2006 May 15;106(10):2104-12.</citation>
    <PMID>16604564</PMID>
  </reference>
  <reference>
    <citation>Li CI, Daling JR, Malone KE. Age-specific incidence rates of in situ breast carcinomas by histologic type, 1980 to 2001. Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):1008-11.</citation>
    <PMID>15824180</PMID>
  </reference>
  <reference>
    <citation>Lopes N, Sousa B, Martins D, Gomes M, Vieira D, Veronese LA, Milanezi F, Paredes J, Costa JL, Schmitt F. Alterations in Vitamin D signalling and metabolic pathways in breast cancer progression: a study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions. BMC Cancer. 2010 Sep 11;10:483. doi: 10.1186/1471-2407-10-483.</citation>
    <PMID>20831823</PMID>
  </reference>
  <reference>
    <citation>Ma Y, Zhang P, Wang F, Yang J, Liu Z, Qin H. Association between vitamin D and risk of colorectal cancer: a systematic review of prospective studies. J Clin Oncol. 2011 Oct 1;29(28):3775-82. doi: 10.1200/JCO.2011.35.7566. Epub 2011 Aug 29. Review.</citation>
    <PMID>21876081</PMID>
  </reference>
  <reference>
    <citation>Martin-Herranz A, Salinas-Hern√°ndez P. Vitamin D supplementation review and recommendations for women diagnosed with breast or ovary cancer in the context of bone health and cancer prognosis/risk. Crit Rev Oncol Hematol. 2015 Oct;96(1):91-9. doi: 10.1016/j.critrevonc.2015.05.006. Epub 2015 May 19. Review.</citation>
    <PMID>26068240</PMID>
  </reference>
  <reference>
    <citation>Pan H, Cai N, Li M, Liu GH, Izpisua Belmonte JC. Autophagic control of cell 'stemness'. EMBO Mol Med. 2013 Mar;5(3):327-31. doi: 10.1002/emmm.201201999. Review.</citation>
    <PMID>23495139</PMID>
  </reference>
  <reference>
    <citation>Sanders KM, Stuart AL, Williamson EJ, Simpson JA, Kotowicz MA, Young D, Nicholson GC. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA. 2010 May 12;303(18):1815-22. doi: 10.1001/jama.2010.594. Erratum in: JAMA. 2010 Jun 16;303(23):2357.</citation>
    <PMID>20460620</PMID>
  </reference>
  <reference>
    <citation>Schleck ML, Souberbielle JC, Jandrain B, Da Silva S, De Niet S, Vanderbist F, Scheen A, Cavalier E. A Randomized, Double-Blind, Parallel Study to Evaluate the Dose-Response of Three Different Vitamin D Treatment Schemes on the 25-Hydroxyvitamin D Serum Concentration in Patients with Vitamin D Deficiency. Nutrients. 2015 Jul 3;7(7):5413-22. doi: 10.3390/nu7075227.</citation>
    <PMID>26151178</PMID>
  </reference>
  <reference>
    <citation>Schnitt SJ. The transition from ductal carcinoma in situ to invasive breast cancer: the other side of the coin. Breast Cancer Res. 2009;11(1):101. doi: 10.1186/bcr2228. Epub 2009 Feb 27.</citation>
    <PMID>19291276</PMID>
  </reference>
  <reference>
    <citation>Wahler J, So JY, Kim YC, Liu F, Maehr H, Uskokovic M, Suh N. Inhibition of the transition of ductal carcinoma in situ to invasive ductal carcinoma by a Gemini vitamin D analog. Cancer Prev Res (Phila). 2014 Jun;7(6):617-26. doi: 10.1158/1940-6207.CAPR-13-0362. Epub 2014 Apr 1.</citation>
    <PMID>24691501</PMID>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 11, 2016</study_first_submitted>
  <study_first_submitted_qc>October 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2016</study_first_posted>
  <results_first_submitted>October 20, 2020</results_first_submitted>
  <results_first_submitted_qc>November 20, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 16, 2020</results_first_posted>
  <last_update_submitted>November 20, 2020</last_update_submitted>
  <last_update_submitted_qc>November 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 21, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/99/NCT02936999/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment Group</title>
          <description>Patients will receive 100,000 IU PO loading dose at Day 1. The loading dose must be administered to the patient at the investigator's site.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment Group</title>
          <description>Patients will receive 100,000IU PO loading dose at Day 1. The loading dose must be administered to the patient at the investigator's site.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Ki 67 Measured</title>
        <description>The proliferation index measured by Ki67 will be described for both baseline (pre) and surgical (post) vitamin D supplementation. A paired t-test or the non-parametric Wilcoxon signed-rank test will be used when appropriate to compare patients' outcome between baseline and after-treatment.</description>
        <time_frame>28 days +/- 3 days from Day 1 of treatment</time_frame>
        <population>The study was terminated due to low enrollment and lack of funding; therefore no data were collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>Patients will receive 100,000IU PO loading dose at Day 1. The loading dose must be administered to the patient at the investigator's site.</description>
          </group>
        </group_list>
        <measure>
          <title>Ki 67 Measured</title>
          <description>The proliferation index measured by Ki67 will be described for both baseline (pre) and surgical (post) vitamin D supplementation. A paired t-test or the non-parametric Wilcoxon signed-rank test will be used when appropriate to compare patients' outcome between baseline and after-treatment.</description>
          <population>The study was terminated due to low enrollment and lack of funding; therefore no data were collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Levels of Proteins of the Autophagy Pathway, LC3B</title>
        <description>Descriptive statistics (N, mean, median, Min, Max, STD for continuous variables, and N, proportion for categorical variables) will be used to summarize patients' demographics as well as lab results. . A paired t-test or the non-parametric Wilcoxon signed-rank test will be used when appropriate to compare patients' outcome between baseline and after-treatment. A p-value of &lt;0.05 will be considered statistically significant.</description>
        <time_frame>28 days +/- 3 days from Day 1 of treatment</time_frame>
        <population>The study was terminated due to low enrollment and lack of funding therefore no data were collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D3</title>
            <description>Patients will be dispensed cholecalciferol, 32 capsules/bottle of 1cap/4000 IU PO QD on Day 1 visit to take home. Bottle must be labeled with instructions on how to take the drug and the assigned patient ID number. Patients will be instructed to take 1 capsule per day, with water, for 29 days using the dispensed study bottle. They will be instructed to stop taking their daily vitamin D3 dose after 30 days of treatment. A study drug diary will be provided at Day 1 visit and patients will be instructed to complete the study drug diary daily from Day 2 to Day 30. Patient's report of vitamin-D3 intake from the diary must be reconciled against the number of capsules returned at Day 30 visit.&#xD;
Cholecalciferol: Cholecalciferol 100,000 IU followed by 4000 IU orally once daily for 30 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Levels of Proteins of the Autophagy Pathway, LC3B</title>
          <description>Descriptive statistics (N, mean, median, Min, Max, STD for continuous variables, and N, proportion for categorical variables) will be used to summarize patients' demographics as well as lab results. . A paired t-test or the non-parametric Wilcoxon signed-rank test will be used when appropriate to compare patients' outcome between baseline and after-treatment. A p-value of &lt;0.05 will be considered statistically significant.</description>
          <population>The study was terminated due to low enrollment and lack of funding therefore no data were collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Levels of Proteins of the Autophagy Pathway, ATG7</title>
        <description>Descriptive statistics (N, mean, median, Min, Max, STD for continuous variables, and N, proportion for categorical variables) will be used to summarize patients' demographics as well as lab results. . A paired t-test or the non-parametric Wilcoxon signed-rank test will be used when appropriate to compare patients' outcome between baseline and after-treatment. A p-value of &lt;0.05 will be considered statistically significant.</description>
        <time_frame>28 days +/- 3 days from Day 1 of treatment</time_frame>
        <population>The study was terminated due to low enrollment and lack of funding; therefore no data were collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>Patients will receive 100,000 IU PO loading dose at Day 1. The loading dose must be administered to the patient at the investigator's site.</description>
          </group>
        </group_list>
        <measure>
          <title>Levels of Proteins of the Autophagy Pathway, ATG7</title>
          <description>Descriptive statistics (N, mean, median, Min, Max, STD for continuous variables, and N, proportion for categorical variables) will be used to summarize patients' demographics as well as lab results. . A paired t-test or the non-parametric Wilcoxon signed-rank test will be used when appropriate to compare patients' outcome between baseline and after-treatment. A p-value of &lt;0.05 will be considered statistically significant.</description>
          <population>The study was terminated due to low enrollment and lack of funding; therefore no data were collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Levels of the Calcium Transport Proteins, PMCA2</title>
        <description>Descriptive statistics (N, mean, median, Min, Max, STD for continuous variables, and N, proportion for categorical variables) will be used to summarize patients' demographics as well as lab results. A paired t-test or the non-parametric Wilcoxon signed-rank test will be used when appropriate to compare patients' outcome between baseline and after-treatment. A p-value of &lt;0.05 will be considered statistically significant.</description>
        <time_frame>28 days +/- 3 days from Day 1 of treatment</time_frame>
        <population>The study was terminated due to low enrollment and lack of funding; therefore no data were collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>Patients will receive 100,000 IU PO loading dose at Day 1. The loading dose must be administered to the patient at the investigator's site.</description>
          </group>
        </group_list>
        <measure>
          <title>Levels of the Calcium Transport Proteins, PMCA2</title>
          <description>Descriptive statistics (N, mean, median, Min, Max, STD for continuous variables, and N, proportion for categorical variables) will be used to summarize patients' demographics as well as lab results. A paired t-test or the non-parametric Wilcoxon signed-rank test will be used when appropriate to compare patients' outcome between baseline and after-treatment. A p-value of &lt;0.05 will be considered statistically significant.</description>
          <population>The study was terminated due to low enrollment and lack of funding; therefore no data were collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HER2 Localization</title>
        <description>Descriptive statistics (N, mean, median, Min, Max, STD for continuous variables, and N, proportion for categorical variables) will be used to summarize patients' demographics as well as lab results. A paired t-test or the non-parametric Wilcoxon signed-rank test will be used when appropriate to compare patients' outcome between baseline and after-treatment. A p-value of &lt;0.05 will be considered statistically significant.</description>
        <time_frame>28 days +/- 3 days from Day 1 of treatment</time_frame>
        <population>The study was terminated due to low enrollment and lack of funding; therefore no data were collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>Patients will receive 100,000 IU PO loading dose at Day 1. The loading dose must be administered to the patient at the investigator's site.</description>
          </group>
        </group_list>
        <measure>
          <title>HER2 Localization</title>
          <description>Descriptive statistics (N, mean, median, Min, Max, STD for continuous variables, and N, proportion for categorical variables) will be used to summarize patients' demographics as well as lab results. A paired t-test or the non-parametric Wilcoxon signed-rank test will be used when appropriate to compare patients' outcome between baseline and after-treatment. A p-value of &lt;0.05 will be considered statistically significant.</description>
          <population>The study was terminated due to low enrollment and lack of funding; therefore no data were collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Clinical Assessment and adverse event evaluation will be done at Day 14, Day 21, and on the Post-Op visit on the study</time_frame>
      <desc>Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research.</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment Group</title>
          <description>Patients will receive 100,000 IU PO loading dose at Day 1. The loading dose must be administered to the patient at the investigator's site.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Regulatory Research Coordinator</name_or_title>
      <organization>Inova Health Services</organization>
      <phone>(571) 472-0239</phone>
      <email>elizabeth.gebregeorgis@inova.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

